This condition is autosomal recessive, meaning a child must inherit two defective copies of the LPL gene (or related genes such as APOC2) to manifest disease. Heterozygous carriers are usually asymptomatic.

Who is affected? Symptoms typically appear in early childhood, sometimes as early as infancy, because the metabolic block is present from birth. The condition occurs in roughly 1 in 1 million individuals worldwide, with slightly higher prevalence in communities with a high rate of consanguineous marriages (e.g., certain Middle‑Eastern and South‑Asian populations).^[1][2]

Symptoms

Because the hallmark is extreme hypertriglyceridemia, clinical manifestations are related to the deposition of fat and the toxic effect of high triglycerides on vessels and the pancreas. Common and less‑common symptoms include:

• Pancreatitis – sudden, severe upper‑abdominal pain radiating to the back; nausea/vomiting; may be recurrent.
• Eruptive xanthomas – eruptive, yellow‑red papules 1–4 mm in diameter, most often on the buttocks, shoulders, extensor surfaces of the arms and legs.
• Plane (flat) xanthomas – smooth, yellowish plaques on the eyelids (xanthelasma), neck, or trunk.
• Tendon xanthomas – firm, nodular lumps over tendons (e.g., Achilles, extensor tendons of the hands).
• Hepatosplenomegaly – enlarged liver and spleen due to lipid accumulation.
• Milky or "lipemic" plasma – visible milky appearance of fasting blood samples.
• Fatigue, abdominal fullness – from hepatic congestion.
• Delayed growth or failure to thrive in infants, secondary to malabsorption and chronic inflammation.
• Peripheral neuropathy (rare) – due to lipid deposition in nerve sheaths.

Causes and Risk Factors

Genetic Basis

Type I hyperlipoproteinemia is most often caused by:

• Mutations in the LPL gene (lipoprotein lipase) – the enzyme that hydrolyzes triglycerides in chylomicrons and VLDL.
• Mutations in APOC2 – apolipoprotein C‑II, a co‑factor that activates LPL.
• Rarely, defects in GPIHBP1 or LMF1, proteins required for LPL transport and maturation.

Inheritance

The disease follows an autosomal recessive pattern. If both parents are carriers, each pregnancy carries a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected, non‑carrier child.

Additional Risk Factors

• Consanguineous marriage (higher probability of inheriting two defective alleles).
• Secondary contributors that raise triglycerides (excess alcohol, uncontrolled diabetes, high‑fat diet) can worsen the clinical picture, though they do not cause the disease.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, laboratory testing, and genetic confirmation.

Laboratory Tests

• Fasting lipid panel – triglycerides often >2,000 mg/dL; total cholesterol may be modestly elevated; LDL‑C and HDL‑C are usually low.
• Post‑prandial lipid profile – persistently high triglycerides even after 12‑hour fast.
• Lipoprotein electrophoresis or ultracentrifugation – shows a predominance of chylomicrons.
• Serum amylase and lipase – elevated during acute pancreatitis episodes.
• LPL activity assay – measured in post‑heparin plasma; markedly reduced or absent in Type I.

Imaging

• Abdominal ultrasound or CT if pancreatitis is suspected (pancreatic edema, fluid collections).
• Ultrasound of liver/spleen to assess hepatosplenomegaly.

Genetic Testing

Sequencing of LPL, APOC2, GPIHBP1, and LMF1 confirms the diagnosis in >90 % of cases and guides family counseling.^[3]

Diagnostic Criteria (summary)

1. Fasting triglycerides >1,000 mg/dL (often >2,000 mg/dL).
2. Presence of chylomicronemia on electrophoresis.
3. Reduced/absent LPL activity or pathogenic mutation in a related gene.
4. Absence of secondary causes (e.g., uncontrolled diabetes, hypothyroidism, medication).

Treatment Options

Because the underlying enzyme deficiency cannot be permanently “cured” with current drugs, treatment focuses on lowering triglycerides, preventing pancreatitis, and managing xanthomas.

Dietary Therapy

• Very‑low‑fat diet – <5 % of total calories from fat (≈20 g/day), split into multiple small meals.
• Medium‑chain triglyceride (MCT) oil – provides calories without requiring LPL for absorption.
• Restriction of simple sugars – reduces hepatic VLDL synthesis.
• Daily vitamin supplementation (A, D, E, K) because fat‑soluble vitamin absorption may be compromised.

Pharmacologic Therapy

• Omega‑3 fatty acid ethyl esters (e.g., icosapent ethyl) – modest triglyceride reduction; safe in pregnancy.
• Fibrates (gemfibrozil, fenofibrate) – generally ineffective in pure LPL deficiency but may be tried if residual activity exists.
• Niacin – limited benefit; can worsen glucose intolerance.
• Lomitapide or Mipomersen – approved for homozygous familial hypercholesterolemia, not for Type I; not recommended.

Enzyme Replacement & Emerging Therapies

• Alipogene tiparvovec (Glybera) – a gene‑therapy product delivering a functional LPL gene via adeno‑associated virus. Approved in Europe (2012) but withdrawn due to cost and limited availability. Clinical trials showed a 30‑50 % reduction in triglycerides for up to 12 months.^[4]
• Experimental LPL‑mimetic peptides – currently in phase II trials; early data suggest acute triglyceride lowering.

Procedural Options

• Plasmapheresis – rapid removal of triglyceride‑rich plasma during acute pancreatitis; provides short‑term control (drops triglycerides by 50‑70 %). Typically reserved for life‑threatening hypertriglyceridemia.

Management of Xanthomas

• Optimizing triglyceride control often leads to gradual flattening of eruptive xanthomas.
• Refractory or cosmetically significant lesions may be removed surgically or by laser therapy after lipid levels are stable.

Living with Xanthomatosis (Hyperlipoproteinemia Type I)

Adapting daily habits is essential for a good quality of life.

• Meal planning – use a diet‑tracking app to stay under the fat limit; prep meals with lean protein, vegetables, and MCT‑based products.
• Hydration – drink at least 2 L of water daily; helps maintain plasma volume and reduces pancreatitis risk.
• Physical activity – low‑impact aerobic exercise (walking, swimming) 150 min/week improves insulin sensitivity and may modestly lower triglycerides.
• Regular labs – fasting lipid panel every 3 months (or more often after dietary changes). Monitor liver enzymes and vitamin levels.
• Vaccinations – annual influenza and pneumococcal vaccines reduce infection‑related triglyceride spikes.
• Family screening – test siblings and parents for carrier status; provide genetic counseling.
• Emergency plan – keep a written plan for acute abdominal pain (fast‑acting oral analgesics, when to call EMS).

Prevention

Because the disease is genetic, primary prevention is not possible. However, secondary measures can reduce the frequency of complications:

• Strict adherence to the low‑fat diet.
• Avoidance of alcohol and high‑sugar beverages.
• Control of secondary metabolic conditions (diabetes, hypothyroidism).
• Early detection of pancreatitis signs and prompt medical evaluation.
• Pre‑conception counseling for women with the disorder – pregnancy increases triglycerides; close monitoring is required.

Complications

If untreated or poorly controlled, patients face serious health risks:

• Acute pancreatitis – occurs in 30‑40 % of patients by age 30; can be recurrent and lead to necrotizing pancreatitis or chronic pancreatic insufficiency.
• Pancreatitis‑related mortality – estimated 5‑10 % mortality in severe cases.
• Pancreatic pseudocysts – may require drainage.
• Hepatic steatosis & cirrhosis – chronic lipid accumulation in the liver.
• Cardiovascular disease – despite normal LDL‑C, extreme triglycerides contribute to atherosclerosis; risk rises with age and additional risk factors.
• Psychosocial impact – visible xanthomas can affect self‑esteem; depression is reported in up to 15 % of adults.

When to Seek Emergency Care

References

1. American Heart Association. Familial Hypertriglyceridemia and Chylomicronemia Syndromes. 2022.
2. World Health Organization. Genetic Disorders: Rare Diseases. 2021.
3. Nordestgaard BG, et al. “Genetics of Hypertriglyceridemia.” Nat Rev Endocrinol. 2020;16(8):475‑490.
4. Theroux J, et al. “Long‑term efficacy and safety of alipogene tiparvovec in lipoprotein lipase deficiency.” J Lipid Res. 2019;60(4):745‑754.